Metabolic dysfunction, rather than steatotic liver disease (SLD), seems to be the main driver of chronic kidney disease (CKD) risk.

A new study published in the journal of Frontiers in Cardiovascular Medicine revealed that Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) were associated with improved left ...

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with ...

The clinical results were presented by Dr. Amish Raval, M.D., Professor of Medicine at University of Wisconsin School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal ...

As American Heart Month closes out, medical experts are putting the spotlight on a less publicized cardiovascular issue: ...

Researchers from Queen Mary University of London have found that a medication originally developed for glycemic control can reverse serious heart damage—not by controlling blood sugar as originally ...

The findings, published this month in Nature Cardiovascular Research, reveal a previously unknown link between immune ...

Researchers from the laboratory of Dr. Sufansa Sawamiphak, head of the group for the study of cardiovascular-hematopoietic ...

When you hear a word like “failure,” especially in the context of “heart failure,” it’s easy for your mind to turn dark. It sounds daunting and untreatable. Those are pretty scary thoughts (to ...

A modest modification of daily dietary habits resulted in a visible change within the human body in only two months. Research ...

Researchers discover a gut-brain-heart axis where the bacterial metabolite IAA regulates hypocretin neurons to control heart stiffness and blood pressure.

Hypertension and heart failure affect millions worldwide. Yet in many patients, doctors cannot fully explain why the heart ...